Duchenne muscular dystrophy (DMD) is the most common and most rapidly progressive muscular dystrophy, with most patients losing the ability to walk by 12 years of age and requiring ventilatory support by 25 years of age.
Before the use of cardioprotective drugs and respiratory muscle aids, respiratory complications were responsible for 80% of deaths and cardiac complications were responsible for approximately 20%. Survival past 30 years of age is no longer rare, with 10% to 40% of patients with DMD surviving to age 40 in centres that use non-invasive means of respiratory support.
The development of acute respiratory failure, previously considered inevitable, can be preventable for most patients.
Severe scoliosis and the need for corrective surgery can be avoided, and the need for mechanical ventilation delayed, by early and aggressive use of corticosteroids.
With a few exceptions, all generalised muscle disease can be managed using the principles for managing DMD.
Muscular dystrophies are progressive, generalised diseases of muscle, most often caused by defective or specifically absent glycoproteins (e.g., dystrophin) in the muscle membrane. All muscular dystrophies are characterised by ongoing degeneration and re-generation of muscle fibres. The most common and rapidly progressive muscular dystrophy is Duchenne muscular dystrophy (DMD). This is X-linked and diagnosed by the finding of absent dystrophin on muscle biopsy. Other X-linked muscular dystrophies include Becker muscular dystrophy (BMD), which is characterised by diminished quantity or quality of dystrophin in muscle biopsy specimens. BMD is a milder form of DMD. Diagnosis can be confirmed using multiplex ligation-dependent probe amplification or full sequencing of the dystrophin gene. This topic will mainly discuss DMD.
History and exam
Consultant Paediatric Neurologist
Great Ormond Street Hospital for Children
PM received education and travel grants from PTC therapeutics in 2016 for a conference. He is principal investigator for the SIDEROS trial for idebenone in Duchenne muscular dystrophy sponsored by Santhera Pharmaceuticals. He lectured on muscular dystrophies at the Practical Neurology study days in 2017 and 2018.
Dr Pinki Munot would like to gratefully acknowledge Dr John R. Bach, Dr Aravindhan Veerapandiyan, and Dr Bilal Saulat, previous contributors to this topic. JRB, AV, and BS declare that they have no competing interests.
Assistant Professor of Medicine
Department of Medicine/Neurology
Duke University Medical Center
LDH-W declares that she has no competing interests.
Associate Professor Neurology and Regenerative Medicine
Wake Forest University Health Sciences
MKC declares that he has no competing interests.
Consultant Paediatric Neurologist
Great Ormond Street Hospital for Children NHS Trust
AM has been paid an honorarium for giving lectures at the Imperial College Educative Training Courses for GPs and post-graduate doctors. AM is the lead author of the Cochrane review of corticosteroids in Duchenne muscular dystrophy. He is also the Lead Clinician of the NorthStar Clinical Network for Management of Neuromuscular Disorders in the UK.
Senior Lecturer and Consultant Neurologist
Department of Clinical Neuroscience
UCL Institute of Neurology
RWO is an author of a reference cited in this topic.
Use of this content is subject to our disclaimer